	US 12,486,538 B2
	Methods of diagnosing alzheimer's disease and risk of progression to alzheimer's disease
Salvador Soriano, Loma Linda, CA (US); and Michael Castello, Loma Linda, CA (US)
Assigned to Loma Linda University Health, Loma Linda, CA (US)
Filed by Loma Linda University Health, Loma Linda, CA (US)
Filed on Jun. 6, 2023, as Appl. No. 18/206,133.
Application 18/206,133 is a continuation of application No. 16/467,783, granted, now 11,708,609, previously published as PCT/US2017/065367, filed on Dec. 8, 2017.
Claims priority of provisional application 62/432,091, filed on Dec. 9, 2016.
Prior Publication US 2024/0026452 A1, Jan. 25, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C12Q 1/6883 (2018.01); A61B 5/00 (2006.01); G01N 33/50 (2006.01); G01N 33/68 (2006.01)

CPC C12Q 1/6883 (2013.01) [A61B 5/00 (2013.01); G01N 33/5023 (2013.01); G01N 33/6896 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/136 (2013.01); C12Q 2600/158 (2013.01); G01N 2500/10 (2013.01); G01N 2800/2821 (2013.01); G01N 2800/50 (2013.01); G01N 2800/52 (2013.01)]

14 Claims

1. A method of treating a subject at risk of progressing to Alzheimer's disease, the method comprising:

detecting one or more of (i) a decreased level of expression of a rhotekin 2 (RTKN2) mRNA or protein, (ii) a decreased level of microtubule-associated Ser/Thr kinase 4 (MAST4) mRNA or protein, (iii) an increased level of binding of forkhead box O1 (FOXO1) to the RTKN2 promoter, or (iv) a decreased level of binding of amyloid precursor protein (APP) or a fragment thereof comprising the APP intracellular domain to the MAST4 promoter in a sample containing a brain issue of the subject relative to a reference value;

prognosing the subject as being at risk of progressing to Alzheimer's disease; and

administering one or more therapeutic interventions to the subject, thereby treating the subject.